semathin semaglutide GLP-1 Receptor Agonist Research Reference Weight Loss Benefits of Semaglutide

Dosing schedule, week-by-week expectations, side-effect timeline, food strategies during titration, the Wegovy vs Ozempic distinction

doi: 10.1016/S0140-6736(14)60976-4 [DOI] [PubMed] [Google Scholar] 110

Obesity SURMOUNT-1 Trial In adults with obesity (without diabetes): Tirzepatide (15 mg) : 20.9% average body weight reduction over 72 weeks Semaglutide (2.4 mg) (based on STEP trials): ~14.9% average reduction STEP 5 Long-Term Results Semaglutide also demonstrated durable effects: At 104 weeks, patients maintained ~15% weight loss on semaglutide 2.4 mg (STEP 5) SELECT Trial Cardiovascular Benefit Semaglutide significantly reduced major adverse cardiovascular events by 20% in people with obesity and pre-existing heart diseaseindicating benefit beyond weight loss

Water reintroduces the possibility of hydrolysis, oxidation, and microbial contamination

American Journal of Clinical Nutrition, 115 (3), 608-618